Photo from wikipedia
Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss with an acceptable safety profile in women with uterine leiomyomas. Click to show full abstract
Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss with an acceptable safety profile in women with uterine leiomyomas.
Keywords:
women heavy;
uterine leiomyomas;
elagolix treatment;
heavy menstrual;
treatment months;
months women
Journal Title: Obstetrics and Gynecology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Obstetrics and Gynecology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!